<DOC>
	<DOCNO>NCT01562028</DOCNO>
	<brief_summary>Rationale : Advanced non-small-cell lung cancer ( NSCLC ) patient harbour epidermal growth factor receptor ( EGFR ) mutation ( del19 L858R ) show impressive progression-free survival 9 14 month treat erlotinib . However , presence EGFR mutation imperfectly predict outcome . The investigator hypothesize progression-free survival could influence pretreatment EGFR T790M mutation component DNA repair pathway . The investigator propose model treatment whereby patient EGFR mutation ( single T790M ) attain benefit long overall PFS treat erlotinib plus bevacizumab . When patient group BRCA1 mRNA level T790M hypothesis combination erlotinib plus bevacizumab improve PFS subgroup .</brief_summary>
	<brief_title>BELIEF ( Bevacizumab ErLotinib In EGFR Mut+ NSCLC )</brief_title>
	<detailed_description>Objectives : 1 . To determine long-term outcome patient advance non-squamous NSCLC harbour EGFR mutation without T790M mutation diagnosis treat combination erlotinib bevacizumab . Primary endpoint : progression-free survival 2 . To evaluate efficacy tolerability combination 3 . To evaluate correlation BRCA1 mRNA AEG-1 mRNA expression T790M progression-free survival 4 . To monitor EGFR mutation ( include T790M ) serum plasma longitudinally 5 . To evaluate molecular biomarkers relate EGFR TKI bevacizumab Design : This multinational , multi-center phase II trial erlotinib plus bevacizumab patient advance non-squamous NSCLC harbour EGFR mutation confirm central re-assessment . Patients stratify two subgroup , without EGFR T790M mutation . The stratification do inclusion patient . Sample size : 102 patient</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age â‰¥ 18 year ECOG performance status 02 Adequate haematological function , coagulation , liver function renal function Pathological diagnosis predominantly nonsquamous , nonsmallcell lung cancer ( NSCLC ) TNM version 7 stage IV disease include M1a ( malignant effusion ) M1b ( distant metastasis ) , locally advanced disease amenable curative treatment ( include patient progress radiochemotherapy stage III disease ) Measurable evaluable disease ( accord RECIST 1.1 criterion ) . Centrally confirm EGFR exon 19 deletion ( del19 ) exon 21 mutation ( L858R ) Patients increase risk bleed Patients clinically significant cardiovascular disease Patients history thrombosis thromboembolism 6 month prior treatment Patients gastrointestinal problem Patients neurologic problem Patients past 5 year previous concomitant malignancy EXCEPT adequately treat basal squamous cell carcinoma skin , situ carcinoma cervix bladder , situ breast carcinoma . Patients know significant ophthalmologic anomaly ocular surface Patients receive prior chemotherapy metastatic disease Patients receive previous treatment lung cancer drug target EGFR VEGF Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>non-squamous</keyword>
	<keyword>EGFR</keyword>
	<keyword>mutation</keyword>
</DOC>